Gain-of-function experiment with constitutively active KRASG12V enhanced glioblastoma sensitivity to CDDP measured by apoptosis and viability; interestingly, specific post-translational modification in HVR region altered sensitivity to cisplatin and/or MEK inhibition. This evidence concerns the gene MAP2K7 and glioblastoma.